Skip to content
TrialScanner

NCT02924402

Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies

Phase 1CompletedXNCRLead

Registry record

Lead sponsor
Xencor, Inc.
Conditions
B-cell Non-Hodgkins Lymphoma; Chronic Lymphocytic Leukemia
Primary completion
Apr 2024Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT02924402 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT02924402: Study to Evaluate Safety and... | TrialScanner